aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in 2011, GlucoSentient, Inc. is a US-based company located in Champaign, specializing in the manufacturing of in vitro and in vivo diagnostic substances. The company's core mission is to revolutionize the Blood Glucose Meter (BGM) by transforming it into a versatile diagnostic platform. GlucoSentient aims to leverage the widespread use and proven reliability of BGMs to create a powerful tool capable of measuring various health indicators, thereby enhancing diagnostic capabilities for millions of diabetics and potentially other patient groups globally.
GlucoSentient has garnered attention for its innovative approach to medical diagnostics, though specific notable affiliated people and investors are not publicly detailed. The company’s key achievement lies in its development of an enhanced BGM technology that promises to expand the utility of this common medical device beyond glucose measurement. This innovation positions GlucoSentient as a significant player in the diagnostic technology market, with the potential to impact healthcare practices and patient outcomes positively.
Operating Status
Active
Main Product(s)
Diagnostic Substances
Technology
Analytics
Tags
Biotech, Healthtech
Model Types
Hardware, Software
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
United States
When was GlucoSentient founded?
GlucoSentient was founded in 2011.
Where is GlucoSentient's headquarters located?
GlucoSentient's headquarters is located in Champaign, IL, US.
When was GlucoSentient's last funding round?
GlucoSentient's most recent funding round was for $900k (USD) in September 2013.
How many employees does GlucoSentient have?
GlucoSentient has 7 employees as of Feb 5, 2024.
How much has GlucoSentient raised to-date?
As of July 05, 2023, GlucoSentient has raised a total of $1.1M (USD) since Sep 16, 2013.
Add Comparison
Total Raised to Date
$1.1M
USD
Last Update Sep 16, 2013
Last Deal Details
$900k
USD
Sep 16, 2013
Grant
Total Employees Over Time
7
As of Feb 2024
GlucoSentient Address
60 Hazelwood Dr
Champaign,
Illinois
61820
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts